Staidson Beijing Biopharma Financial Flexibility Index
Staidson Beijing Biopharma financial flexibility index. Staidson Beijing Biopharma (300204) has a Financial Flexibility Index of -0.06x as of September 2025. Free cash flow of CN¥-23.52 Million (operating CF CN¥-39.18 Million minus capex CN¥15.66 Million) represents 0% of total liabilities (CN¥404.22 Million). Explore capital reinvestment ratio of Staidson Beijing Biopharma to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Staidson Beijing Biopharma (2007–2025)
Financial flexibility index of Staidson Beijing Biopharma from 2007 to 2025. Historical Financial Flexibility Index trend for Staidson Beijing Biopharma across 19 annual periods. Check cash flow reinvestment rate of Staidson Beijing Biopharma to assess the company's total reinvestment commitment from operating cash flow.
Staidson Beijing Biopharma Financial Flexibility Index by Year (2007–2025)
Staidson Beijing Biopharma financial flexibility index by year from 2007 to 2025. Year-by-year free cash flow to debt coverage for Staidson Beijing Biopharma. For the full cash flow conversion analysis, see 300204 cash generation efficiency.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.11x | CN¥-49.05 Million | CN¥-125.68 Million | CN¥459.48 Million | ▲ +38.1% |
| 2024 | -0.17x | CN¥-40.16 Million | CN¥-63.68 Million | CN¥232.85 Million | ▲ +72.5% |
| 2023 | -0.63x | CN¥-195.32 Million | CN¥-227.47 Million | CN¥311.55 Million | ▼ -66.1% |
| 2022 | -0.38x | CN¥-119.09 Million | CN¥-175.60 Million | CN¥315.45 Million | ▲ +1.5% |
| 2021 | -0.38x | CN¥-105.83 Million | CN¥-162.07 Million | CN¥276.25 Million | ▼ -56.6% |
| 2020 | -0.24x | CN¥-65.73 Million | CN¥-114.60 Million | CN¥268.70 Million | ▼ -153.3% |
| 2019 | 0.46x | CN¥104.25 Million | CN¥44.34 Million | CN¥227.18 Million | ▼ -44.6% |
| 2018 | 0.83x | CN¥260.54 Million | CN¥165.08 Million | CN¥314.30 Million | ▲ +8.5% |
| 2017 | 0.76x | CN¥320.19 Million | CN¥273.64 Million | CN¥419.14 Million | ▲ +38.2% |
| 2016 | 0.55x | CN¥239.00 Million | CN¥212.55 Million | CN¥432.32 Million | ▼ -16.1% |
| 2015 | 0.66x | CN¥254.96 Million | CN¥231.01 Million | CN¥387.06 Million | ▼ -11.4% |
| 2014 | 0.74x | CN¥221.32 Million | CN¥206.85 Million | CN¥297.54 Million | ▲ +41.4% |
| 2013 | 0.53x | CN¥134.39 Million | CN¥111.36 Million | CN¥255.47 Million | ▼ -32.2% |
| 2012 | 0.78x | CN¥149.07 Million | CN¥90.19 Million | CN¥192.15 Million | ▼ -78.6% |
| 2011 | 3.62x | CN¥171.36 Million | CN¥87.01 Million | CN¥47.32 Million | ▲ +144.4% |
| 2010 | 1.48x | CN¥146.15 Million | CN¥63.91 Million | CN¥98.66 Million | ▼ -22.6% |
| 2009 | 1.91x | CN¥55.56 Million | CN¥42.37 Million | CN¥29.03 Million | ▲ +69.4% |
| 2008 | 1.13x | CN¥33.03 Million | CN¥16.23 Million | CN¥29.25 Million | ▲ +849.6% |
| 2007 | 0.12x | CN¥5.75 Million | CN¥5.41 Million | CN¥48.35 Million | — |